The changing immune system in sepsis is individualized immuno-modulatory therapy the answer?

Virulence

Volumn 5, Issue 1, 2014, Pages 45-56

  Boomer, Jonathan S ^a   Green, Jonathan M ^a   Hotchkiss, Richard S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adaptive immunity; Cell exhaustion; Immune suppression; Immune therapy; Sepsis

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CD69 ANTIGEN; CYTOCHROME C; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MITOGEN ACTIVATED PROTEIN KINASE; PATTERN RECOGNITION RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN BCL XL; PROTEIN BID; RECOMBINANT GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; UNINDEXED DRUG;

ADAPTIVE IMMUNITY; APOPTOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXHAUSTION; CELL SURVIVAL; CELLULAR, SUBCELLULAR AND MOLECULAR BIOLOGICAL PHENOMENA AND FUNCTIONS; CYTOKINE STORM; EFFECTOR CELL; HOST SUSCEPTIBILITY; HUMAN; IMMUNE DYSFUNCTION; IMMUNE PARALYSIS; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOTHERAPY; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NEUTROPHIL; NONHUMAN; PHAGOCYTOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; SUPPRESSOR CELL;

ADAPTIVE IMMUNITY; CELL EXHAUSTION; IMMUNE SUPPRESSION; IMMUNE THERAPY; SEPSIS;

ADAPTIVE IMMUNITY; APOPTOSIS; CYTOKINES; HUMANS; IMMUNE TOLERANCE; IMMUNITY, INNATE; IMMUNOTHERAPY; INDIVIDUALIZED MEDICINE; INFLAMMATION; SEPSIS; T-LYMPHOCYTES;

EID: 84891645973     PISSN: 21505594     EISSN: 21505608     Source Type: Journal    
DOI: 10.4161/viru.26516     Document Type: Review

References (152)

1. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, et al.; International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327; PMID:18158437;http://dx.doi.org/10.1097/01.CCM.0000298158.12101.41
2. Balk RA. Optimum treatment of severe sepsis and septic shock: evidence in support of the recommendations. Dis Mon 2004; 50:168-213; PMID:15133467; http://dx.doi.org/10.1016/j.disamonth.2003.12.003
3. Christaki E, Anyfanti P, Opal SM. Immunomodulatory therapy for sepsis: an update. Expert Rev Anti Infect Ther 2011; 9:1013-33; PMID:22029521; http://dx.doi.org/10.1586/eri.11.122
4. Giamarellos-Bourboulis EJ, Raftogiannis M. The immune response to severe bacterial infections: consequences for therapy. Expert Rev Anti Infect Ther 2012; 10:369-80; PMID:22397569; http://dx.doi.org/10.1586/eri.12.2
5. van der Poll T, Opal SM. Host-pathogen interactions in sepsis. Lancet Infect Dis 2008; 8:32-43; PMID:18063412; http://dx.doi.org/10.1016/S1473-3099(07)70265-7
6. Ward PA, Bosmann M. A historical perspective on sepsis. Am J Pathol 2012; 181:2-7; PMID:22642906; http://dx.doi.org/10.1016/j.ajpath.2012.05.003
7. Davies MG, Hagen PO. Systemic inflammatory response syndrome. Br J Surg 1997; 84:920-35; PMID:9240130; http://dx.doi.org/10.1002/bjs.1800840707
8. Cinel I, Opal SM. Molecular biology of inflammation and sepsis: a primer. Crit Care Med 2009; 37:291-304; PMID:19050640; http://dx.doi.org/10.1097/CCM.0b013e31819267fb
9. Casey LC. Immunologic response to infection and its role in septic shock. Crit Care Clin 2000; 16:193-213; PMID:10768079; http://dx.doi.org/10.1016/S0749-0704(05)70107-X
10. Opal SM. Immunologic alterations and the pathogenesis of organ failure in the ICU. Semin Respir Crit Care Med 2011; 32:569-80; PMID:21989693; http://dx.doi.org/10.1055/s-0031-1287865
11. Angus DC. The search for effective therapy for sepsis: back to the drawing board? JAMA 2011; 306:2614-5; PMID:22187284; http://dx.doi.org/10.1001/jama.2011.1853
12. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto A, et al.; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353:1332-41; PMID:16192478; http://dx.doi.org/10.1056/NEJMoa050935
13. Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, Abd-Allah SA, Levy H, Angle R, Wang D, et al.; REsearching severe Sepsis and Organ dysfunction in children: a gLobal perspective (RESOLVE) study group. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007; 369:836-43; PMID:17350452; http://dx.doi.org/10.1016/S0140-6736(07)60411-5
14. Opal SM, LaRosa SP. Recombinant human activated protein C as a therapy for severe sepsis: lessons learned? Am J Respir Crit Care Med 2013; 187:1041-3; PMID:23675711; http://dx.doi.org/10.1164/rccm.201303-0505ED
15. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 2013; 13:260-8; PMID:23427891; http://dx.doi.org/10.1016/S1473-3099(13)70001-X
16. Cohen J, Opal S, Calandra T. Sepsis studies need new direction. Lancet Infect Dis 2012; 12:503-5; PMID:22742624; http://dx.doi.org/10.1016/S1473-3099(12)70136-6
17. Vincent JL, Sun Q, Dubois MJ. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 2002; 34:1084-93; PMID:11914997; http://dx.doi.org/10.1086/339549
18. Frazier WJ, Hall MW. Immunoparalysis and adverse outcomes from critical illness. [xi.]. Pediatr Clin North Am 2008; 55:647-68, xi; PMID:18501759; http://dx.doi.org/10.1016/j.pcl.2008.02.009
19. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348:138-50; PMID:12519925; http://dx.doi.org/10.1056/NEJMra021333
20. Munford RS, Pugin J. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med 2001; 163:316-21; PMID:11179099; http://dx.doi.org/10.1164/ajrccm.163.2.2007102
21. Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996; 24:1125-8; PMID:8674323; http://dx.doi.org/10.1097/00003246-199607000-00010
22. Wang H, Ma S. The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. Am J Emerg Med 2008; 26:711-5; PMID:18606328; http://dx.doi.org/10.1016/j.ajem.2007.10.031
23. Cavaillon JM, Annane D. Compartmentalization of the inflammatory response in sepsis and SIRS. J Endotoxin Res 2006; 12:151-70; PMID:16719987; http://dx.doi.org/10.1179/096805106X102246
24. Tang BM, Huang SJ, McLean AS. Genome-wide transcription profiling of human sepsis: a systematic review. Crit Care 2010; 14:R237; PMID:21190579; http://dx.doi.org/10.1186/cc9392
25. Kollef KE, Schramm GE, Wills AR, Reichley RM, Micek ST, Kollef MH. Predictors of 30-day mortality and hospital costs in patients with ventilatorassociated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest 2008; 134:281-7; PMID:18682456; http://dx.doi.org/10.1378/chest.08-1116
26. Otto GP, Sossdorf M, Claus RA, Rödel J, Menge K, Reinhart K, Bauer M, Riedemann NC. The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit Care 2011; 15:R183; PMID:21798063; http://dx.doi.org/10.1186/cc10332
27. Monneret G, Venet F, Kullberg BJ, Netea MG. ICUacquired immunosuppression and the risk for secondary fungal infections. Med Mycol 2011; 49(Suppl 1):S17-23; PMID:20718607; http://dx.doi.org/10.3109/13693786.2010.509744
28. Heininger A, Haeberle H, Fischer I, Beck R, Riessen R, Rohde F, Meisner C, Jahn G, Koenigsrainer A, Unertl K, et al. Cytomegalovirus reactivation and associated outcome of critically ill patients with severe sepsis. Crit Care 2011; 15:R77; PMID:21362193; http://dx.doi.org/10.1186/cc10069
29. Ziemann M, Sedemund-Adib B, Reiland P, Schmucker P, Hennig H. Increased mortality in longterm intensive care patients with active cytomegalovirus infection. Crit Care Med 2008; 36:3145-50; PMID:18936696; http://dx.doi.org/10.1097/CCM.0b013e31818f3fc4
30. Kalil AC, Florescu DF. Prevalence and mortality associated with cytomegalovirus infection in nonimmunosuppressed patients in the intensive care unit. Crit Care Med 2009; 37:2350-8; PMID:19531944; http://dx.doi.org/10.1097/CCM.0b013e3181a3aa43
31. Osuchowski MF, Welch K, Yang H, Siddiqui J, Remick DG. Chronic sepsis mortality characterized by an individualized inflammatory response. J Immunol 2007; 179:623-30; PMID:17579084
32. Meakins JL, Pietsch JB, Bubenick O, Kelly R, Rode H, Gordon J, MacLean LD. Delayed hypersensitivity: indicator of acquired failure of host defenses in sepsis and trauma. Ann Surg 1977; 186:241-50; PMID:142452; http://dx.doi.org/10.1097/00000658-197709000-00002
33. Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA. The sepsis seesaw: tilting toward immunosuppression. Nat Med 2009; 15:496-7; PMID:19424209; http://dx.doi.org/10.1038/nm0509-496
34. Hotchkiss RS, Opal S. Immunotherapy for sepsis-a new approach against an ancient foe. N Engl J Med 2010; 363:87-9; PMID:20592301; http://dx.doi.org/10.1056/NEJMcibr1004371
35. Venet F, Chung CS, Monneret G, Huang X, Horner B, Garber M, Ayala A. Regulatory T cell populations in sepsis and trauma. J Leukoc Biol 2008; 83:523-35; PMID:17913974; http://dx.doi.org/10.1189/jlb.0607371
36. Venet F, Chung CS, Kherouf H, Geeraert A, Malcus C, Poitevin F, Bohé J, Lepape A, Ayala A, Monneret G. Increased circulating regulatory T cells (CD4(+) CD25 (+)CD127 (-)) contribute to lymphocyte anergy in septic shock patients. Intensive Care Med 2009; 35:678-86; PMID:18946659; http://dx.doi.org/10.1007/s00134-008-1337-8
37. Leng FY, Liu JL, Liu ZJ, Yin JY, Qu HP. Increased proportion of CD4(+)CD25(+)Foxp3(+) regulatory T cells during the early-stage sepsis in ICU patients. J Microbiol Immunol Infect 2012; (Forthcoming); PMID:22921804; http://dx.doi.org/10.1016/j.jmii.2012.06.012
38. Delano MJ, Scumpia PO, Weinstein JS, Coco D, Nagaraj S, Kelly-Scumpia KM, O'Malley KA, Wynn JL, Antonenko S, Al-Quran SZ, et al. MyD88-dependent expansion of an immature GR-1(+) CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med 2007; 204:1463-74; PMID:17548519; http://dx.doi.org/10.1084/jem.20062602
39. Venet F, Lepape A, Monneret G. Clinical review: flow cytometry perspectives in the ICU - from diagnosis of infection to monitoring of injury-induced immune dysfunctions. Crit Care 2011; 15:231; PMID:22017882; http://dx.doi.org/10.1186/cc10333
40. Ferguson NR, Galley HF, Webster NR. T helper cell subset ratios in patients with severe sepsis. Intensive Care Med 1999; 25:106-9; PMID:10051087; http://dx.doi.org/10.1007/s001340050795
41. Senftleben U, Karin M. The IKK/NF-kappaB pathway. Crit Care Med 2002; 30(Supp):S18-26; PMID:11891403; http://dx.doi.org/10.1097/00003246-200201001-00003
42. Weighardt H, Holzmann B. Role of Toll-like receptor responses for sepsis pathogenesis. Immunobiology 2007; 212:715-22; PMID:18086373; http://dx.doi.org/10.1016/j.imbio.2007.09.010
43. Unsinger J, Kazama H, McDonough JS, Griffith TS, Hotchkiss RS, Ferguson TA. Sepsis-induced apoptosis leads to active suppression of delayed-type hypersensitivity by CD8+ regulatory T cells through a TRAIL-dependent mechanism. J Immunol 2010; 184:6766-72; PMID:20483771; http://dx.doi.org/10.4049/jimmunol.0904054
44. Unsinger J, McDonough JS, Shultz LD, Ferguson TA, Hotchkiss RS. Sepsis-induced human lymphocyte apoptosis and cytokine production in "humanized" mice. J Leukoc Biol 2009; 86:219-27; PMID:19369639; http://dx.doi.org/10.1189/jlb.1008615
45. Boomer JS, Shuherk-Shaffer J, Hotchkiss RS, Green JM. A prospective analysis of lymphocyte phenotype and function over the course of acute sepsis. Crit Care 2012; 16:R112; PMID:22742734; http://dx.doi.org/10.1186/cc11404
46. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, Bricker TL, Jarman SD 2nd, Kreisel D, Krupnick AS, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011; 306:2594-605; PMID:22187279; http://dx.doi.org/10.1001/jama.2011.1829
47. Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, Matuschak GM, Buchman TG, Karl IE. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 1999; 27:1230-51; PMID:10446814; http://dx.doi.org/10.1097/00003246-199907000-00002
48. Hotchkiss RS, Tinsley KW, Swanson PE, Schmieg RE Jr., Hui JJ, Chang KC, Osborne DF, Freeman BD, Cobb JP, Buchman TG, et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 2001; 166:6952-63; PMID:11359857
49. Kasten KR, Tschöp J, Goetzman HS, England LG, Dattilo JR, Cave CM, Seitz AP, Hildeman DA, Caldwell CC. T-cell activation differentially mediates the host response to sepsis. Shock 2010; 34:377-83; PMID:20610943; http://dx.doi.org/10.1097/SHK.0b013e3181dc0845
50. Ayala A, Perl M, Venet F, Lomas-Neira J, Swan R, Chung CS. Apoptosis in sepsis: mechanisms, clinical impact and potential therapeutic targets. Curr Pharm Des 2008; 14:1853-9; PMID:18691096; http://dx.doi.org/10.2174/138161208784980617
51. Hotchkiss RS, Strasser A, McDunn JE, Swanson PE. Cell death. N Engl J Med 2009; 361:1570-83; PMID:19828534; http://dx.doi.org/10.1056/NEJMra0901217
52. Strasser A, Cory S, Adams JM. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J 2011; 30:3667-83; PMID:21863020; http://dx.doi.org/10.1038/emboj.2011.307
53. Chang KC, Unsinger J, Davis CG, Schwulst SJ, Muenzer JT, Strasser A, Hotchkiss RS. Multiple triggers of cell death in sepsis: death receptor and mitochondrial-mediated apoptosis. FASEB J 2007; 21:708-19; PMID:17307841; http://dx.doi.org/10.1096/fj.06-6805com
54. Klener P Jr., Andera L, Klener P, Necas E, Zivný J. Cell death signalling pathways in the pathogenesis and therapy of haematologic malignancies: overview of therapeutic approaches. Folia Biol (Praha) 2006; 52:119-36; PMID:17116284
55. Vaki I, Kranidioti H, Karagianni V, Spyridaki A, Kotsaki A, Routsi C, Giamarellos-Bourboulis EJ. An early circulating factor in severe sepsis modulates apoptosis of monocytes and lymphocytes. J Leukoc Biol 2011; 89:343-9; PMID:21030664; http://dx.doi.org/10.1189/jlb.0410232
56. Arad G, Levy R, Nasie I, Hillman D, Rotfogel Z, Barash U, Supper E, Shpilka T, Minis A, Kaempfer R. Binding of superantigen toxins into the CD28 homodimer interface is essential for induction of cytokine genes that mediate lethal shock. PLoS Biol 2011; 9:e1001149; PMID:21931534; http://dx.doi.org/10.1371/journal.pbio.1001149
57. Schmidt MV, Paulus P, Kuhn AM, Weigert A, Morbitzer V, Zacharowski K, Kempf VA, Brüne B, von Knethen A. Peroxisome proliferator-activated receptor γ-induced T cell apoptosis reduces survival during polymicrobial sepsis. Am J Respir Crit Care Med 2011; 184:64-74; PMID:21471100; http://dx.doi.org/10.1164/rccm.201010-1585OC
58. He KL, Ting AT. A20 inhibits tumor necrosis factor (TNF) alpha-induced apoptosis by disrupting recruitment of TRADD and RIP to the TNF receptor 1 complex in Jurkat T cells. Mol Cell Biol 2002; 22:6034-45; PMID:12167698; http://dx.doi.org/10.1128/MCB.22.17.6034-6045.2002
59. Riedemann NC, Guo RF, Laudes IJ, Keller K, Sarma VJ, Padgaonkar V, Zetoune FS, Ward PA. C5a receptor and thymocyte apoptosis in sepsis. FASEB J 2002; 16:887-8; PMID:12039868
60. Boomer JS, Green JM. An enigmatic tail of CD28 signaling. Cold Spring Harb Perspect Biol 2010; 2:a002436; PMID:20534709; http://dx.doi.org/10.1101/cshperspect.a002436
61. Shiao SL, McNiff JM, Pober JS. Memory T cells and their costimulators in human allograft injury. J Immunol 2005; 175:4886-96; PMID:16210590
62. Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol 2007; 7:803-15; PMID:17893694; http://dx.doi.org/10.1038/nri2171
63. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol 2002; 2:116-26; PMID:11910893; http://dx.doi.org/10.1038/nri727
64. Kitazawa Y, Fujino M, Wang Q, Kimura H, Azuma M, Kubo M, Abe R, Li XK. Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses. Transplantation 2007; 83:774-82; PMID:17414712; http://dx.doi.org/10.1097/01.tp.0000256293.90270.e8
65. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 2012; 30:531-64; PMID:22224781; http://dx.doi.org/10.1146/annurev.immunol.25.022106.141623
66. Kessel A, Bamberger E, Masalha M, Toubi E. The role of T regulatory cells in human sepsis. J Autoimmun 2009; 32:211-5; PMID:19345068; http://dx.doi.org/10.1016/j.jaut.2009.02.014
67. Venet F, Pachot A, Debard AL, Bohe J, Bienvenu J, Lepape A, Powell WS, Monneret G. Human CD4+CD25+ regulatory T lymphocytes inhibit lipopolysaccharide- induced monocyte survival through a Fas/Fas ligand-dependent mechanism. J Immunol 2006; 177:6540-7; PMID:17056586
68. van Dissel JT, van Langevelde P, Westendorp RG, Kwappenberg K, Frölich M. Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 1998; 351:950-3; PMID:9734942; http://dx.doi.org/10.1016/S0140-6736(05)60606-X
69. Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Proversus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis 2000; 181:176-80; PMID:10608764; http://dx.doi.org/10.1086/315214
70. Jiang H, Chess L. Regulation of immune responses by T cells. N Engl J Med 2006; 354:1166-76; PMID:16540617; http://dx.doi.org/10.1056/NEJMra055446
71. Littman DR, Rudensky AY. Th17 and regulatory T cells in mediating and restraining inflammation. Cell 2010; 140:845-58; PMID:20303875; http://dx.doi.org/10.1016/j.cell.2010.02.021
72. Ertel W, Kremer JP, Kenney J, Steckholzer U, Jarrar D, Trentz O, Schildberg FW. Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood 1995; 85:1341-7; PMID:7858264
73. Munoz C, Carlet J, Fitting C, Misset B, Blériot JP, Cavaillon JM. Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 1991; 88:1747-54; PMID:1939659; http://dx.doi.org/10.1172/JCI115493
74. Rigato O, Salomao R. Impaired production of interferon- gamma and tumor necrosis factor-alpha but not of interleukin 10 in whole blood of patients with sepsis. Shock 2003; 19:113-6; PMID:12578117; http://dx.doi.org/10.1097/00024382-200302000-00004
75. Sinistro A, Almerighi C, Ciaprini C, Natoli S, Sussarello E, Di Fino S, Calò-Carducci F, Rocchi G, Bergamini A. Downregulation of CD40 ligand response in monocytes from sepsis patients. Clin Vaccine Immunol 2008; 15:1851-8; PMID:18945879; http://dx.doi.org/10.1128/CVI.00184-08
76. Weighardt H, Heidecke CD, Emmanuilidis K, Maier S, Bartels H, Siewert JR, Holzmann B. Sepsis after major visceral surgery is associated with sustained and interferon-gamma-resistant defects of monocyte cytokine production. Surgery 2000; 127:309-15; PMID:10715987; http://dx.doi.org/10.1067/msy.2000.104118
77. Monneret G, Venet F. A rapidly progressing lymphocyte exhaustion after severe sepsis. Crit Care 2012; 16:140; PMID:22824381; http://dx.doi.org/10.1186/cc11416
78. Yi JS, Cox MA, Zajac AJ. T-cell exhaustion: characteristics, causes and conversion. Immunology 2010; 129:474-81; PMID:20201977; http://dx.doi.org/10.1111/j.1365-2567.2010.03255.x
79. Xiao H, Siddiqui J, Remick DG. Mechanisms of mortality in early and late sepsis. Infect Immun 2006; 74:5227-35; PMID:16926416; http://dx.doi.org/10.1128/IAI.01220-05
80. Bonten MJ, Froon AH, Gaillard CA, Greve JW, de Leeuw PW, Drent M, Stobberingh EE, Buurman WA. The systemic inflammatory response in the development of ventilator-associated pneumonia. Am J Respir Crit Care Med 1997; 156:1105-13; PMID:9351609; http://dx.doi.org/10.1164/ajrccm.156.4.9610002
81. Pelekanou A, Tsangaris I, Kotsaki A, Karagianni V, Giamarellou H, Armaganidis A, Giamarellos-Bourboulis EJ. Decrease of CD4-lymphocytes and apoptosis of CD14-monocytes are characteristic alterations in sepsis caused by ventilator-associated pneumonia: results from an observational study. Crit Care 2009; 13:R172; PMID:19883512; http://dx.doi.org/10.1186/cc8148
82. Abraham E, Laterre PF, Garbino J, Pingleton S, Butler T, Dugernier T, Margolis B, Kudsk K, Zimmerli W, Anderson P, et al.; Lenercept Study Group. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med 2001; 29:503-10; PMID:11373411; http://dx.doi.org/10.1097/00003246-200103000-00006
83. Fisher CJ Jr., Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994; 271:1836-43; PMID:8196140; http://dx.doi.org/10.1001/jama.1994.03510470040032
84. Opal SM, Fisher CJ Jr., Dhainaut JF, Vincent JL, Brase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H, Balk RA, et al. Confirmatory interleukin-1receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997; 25:1115-24; PMID:9233735; http://dx.doi.org/10.1097/00003246-199707000-00010
85. Panacek EA, Marshall JC, Albertson TE, Johnson DH, Johnson S, MacArthur RD, Miller M, Barchuk WT, Fischkoff S, Kaul M, et al.; Monoclonal Anti- TNF: a Randomized Controlled Sepsis Study Investigators. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004; 32:2173-82; PMID:15640628
86. Rice TW, Wheeler AP, Morris PE, Paz HL, Russell JA, Edens TR, Bernard GR. Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab) in severe sepsis. Crit Care Med 2006; 34:2271-81; PMID:16810105; http://dx.doi.org/10.1097/01.CCM.0000230385.82679.34
87. Bellomo R, Tetta C, Ronco C. Coupled plasma filtration adsorption. Intensive Care Med 2003; 29:1222-8; PMID:12830374; http://dx.doi.org/10.1007/s00134-003-1796-x
88. Humes HD, Weitzel WF, Bartlett RH, Swaniker FC, Paganini EP, Luderer JR, Sobota J. Initial clinical results of the bioartificial kidney containing human cells in ICU patients with acute renal failure. Kidney Int 2004; 66:1578-88; PMID:15458454; http://dx.doi.org/10.1111/j.1523-1755.2004.00923.x
89. Tumlin J, Wali R, Williams W, Murray P, Tolwani AJ, Vinnikova AK, Szerlip HM, Ye J, Paganini EP, Dworkin L, et al. Efficacy and safety of renal tubule cell therapy for acute renal failure. J Am Soc Nephrol 2008; 19:1034-40; PMID:18272842; http://dx.doi.org/10.1681/ASN.2007080895
90. Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, Wittebole X, Dugernier T, Perrotin D, Tidswell M, et al.; ACCESS Study Group. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 2013; 309:1154-62; PMID:23512062; http://dx.doi.org/10.1001/jama.2013.2194
91. Balk RA. Pathogenesis and management of multiple organ dysfunction or failure in severe sepsis and septic shock. [vii.]. Crit Care Clin 2000; 16:337-52, vii; PMID:10768085; http://dx.doi.org/10.1016/S0749-0704(05)70113-5
92. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-10; PMID:11445675; http://dx.doi.org/10.1097/00003246-200107000-00002
93. Kasten KR, Prakash PS, Unsinger J, Goetzman HS, England LG, Cave CM, Seitz AP, Mazuski CN, Zhou TT, Morre M, et al. Interleukin-7 (IL-7) treatment accelerates neutrophil recruitment through gamma delta T-cell IL-17 production in a murine model of sepsis. Infect Immun 2010; 78:4714-22; PMID:20823197; http://dx.doi.org/10.1128/IAI.00456-10
94. Flohé SB, Agrawal H, Flohé S, Rani M, Bangen JM, Schade FU. Diversity of interferon gamma and granulocyte-macrophage colony-stimulating factor in restoring immune dysfunction of dendritic cells and macrophages during polymicrobial sepsis. Mol Med 2008; 14:247-56; PMID:18297128; http://dx.doi.org/10.2119/2007-00120.Flohe
95. Bo L, Wang F, Zhu J, Li J, Deng X. Granulocytecolony stimulating factor (G-CSF) and granulocytemacrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Crit Care 2011; 15:R58; PMID:21310070; http://dx.doi.org/10.1186/cc10031
96. Cheng AC, Limmathurotsakul D, Chierakul W, Getchalarat N, Wuthiekanun V, Stephens DP, Day NP, White NJ, Chaowagul W, Currie BJ, et al. A randomized controlled trial of granulocyte colonystimulating factor for the treatment of severe sepsis due to melioidosis in Thailand. Clin Infect Dis 2007; 45:308-14; PMID:17599307; http://dx.doi.org/10.1086/519261
97. Hall MW, Knatz NL, Vetterly C, Tomarello S, Wewers MD, Volk HD, Carcillo JA. Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med 2011; 37:525-32; PMID:21153402; http://dx.doi.org/10.1007/s00134-010-2088-x
98. Rosenbloom AJ, Linden PK, Dorrance A, Penkosky N, Cohen-Melamed MH, Pinsky MR. Effect of granulocyte-monocyte colony-stimulating factor therapy on leukocyte function and clearance of serious infection in nonneutropenic patients. Chest 2005; 127:2139-50; PMID:15947332; http://dx.doi.org/10.1378/chest.127.6.2139
99. Schefold JC, Zeden JP, Pschowski R, Hammoud B, Fotopoulou C, Hasper D, Fusch G, Von Haehling S, Volk HD, Meisel C, et al. Treatment with granulocyte- macrophage colony-stimulating factor is associated with reduced indoleamine 2,3-dioxygenase activity and kynurenine pathway catabolites in patients with severe sepsis and septic shock. Scand J Infect Dis 2010; 42:164-71; PMID:19958238; http://dx.doi.org/10.3109/00365540903405768
100. Stephens DP, Thomas JH, Higgins A, Bailey M, Anstey NM, Currie BJ, Cheng AC. Randomized, double-blind, placebo-controlled trial of granulocyte colony-stimulating factor in patients with septic shock. Crit Care Med 2008; 36:448-54; PMID:18216600; http://dx.doi.org/10.1097/01.CCM.0B013E318161E480
101. Nelson S, Belknap SM, Carlson RW, Dale D, DeBoisblanc B, Farkas S, Fotheringham N, Ho H, Marrie T, Movahhed H, et al.; CAP Study Group. A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. J Infect Dis 1998; 178:1075-80; PMID:9806037; http://dx.doi.org/10.1086/515694
102. Nelson S, Heyder AM, Stone J, Bergeron MG, Daugherty S, Peterson G, Fotheringham N, Welch W, Milwee S, Root R. A randomized controlled trial of filgrastim for the treatment of hospitalized patients with multilobar pneumonia. J Infect Dis 2000; 182:970-3; PMID:10950800; http://dx.doi.org/10.1086/315775
103. Root RK, Lodato RF, Patrick W, Cade JF, Fotheringham N, Milwee S, Vincent JL, Torres A, Rello J, Nelson S; Pneumonia Sepsis Study Group. Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med 2003; 31:367-73; PMID:12576938; http://dx.doi.org/10.1097/01.CCM.0000048629.32625.5D
104. Weiss M, Gross-Weege W, Schneider M, Neidhardt H, Liebert S, Mirow N, Wernet P. Enhancement of neutrophil function by in vivo filgrastim treatment for prophylaxis of sepsis in surgical intensive care patients. J Crit Care 1995; 10:21-6; PMID:7538851; http://dx.doi.org/10.1016/0883-9441(95)90027-6
105. Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, Weber-Carstens S, Hasper D, Keh D, Zuckermann H, et al. Granulocytemacrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a doubleblind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009; 180:640-8; PMID:19590022; http://dx.doi.org/10.1164/rccm.200903-0363OC
106. Polk HC Jr., Cheadle WG, Livingston DH, Rodriguez JL, Starko KM, Izu AE, Jaffe HS, Sonnenfeld G. A randomized prospective clinical trial to determine the efficacy of interferon-gamma in severely injured patients. Am J Surg 1992; 163:191-6; PMID:1739172; http://dx.doi.org/10.1016/0002-9610(92)90099-D
107. Wasserman D, Ioannovich JD, Hinzmann RD, Deichsel G, Steinmann GG; The Severe Burns Study Group. Interferon-gamma in the prevention of severe burn-related infections: a European phase III multicenter trial. Crit Care Med 1998; 26:434-9; PMID:9504568; http://dx.doi.org/10.1097/00003246-199803000-00010
108. Dries DJ, Jurkovich GJ, Maier RV, Clemmer TP, Struve SN, Weigelt JA, Stanford GG, Herr DL, Champion HR, Lewis FR, et al. Effect of interferon gamma on infection-related death in patients with severe injuries. A randomized, double-blind, placebo-controlled trial. Arch Surg 1994; 129:1031-41, discussion 1042; PMID:7944932; http://dx.doi.org/10.1001/archsurg.1994.01420340045008
109. Döcke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD, Kox W. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 1997; 3:678-81; PMID:9176497; http://dx.doi.org/10.1038/ nm0697-678
110. Inoue S, Unsinger J, Davis CG, Muenzer JT, Ferguson TA, Chang K, Osborne DF, Clark AT, Coopersmith CM, McDunn JE, et al. IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis. J Immunol 2010; 184:1401-9; PMID:20026737; http://dx.doi.org/10.4049/jimmunol.0902307
111. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood 2001; 97:14- 32; PMID:11133738; http://dx.doi.org/10.1182/blood.V97.1.14
112. Steel JC, Waldmann TA, Morris JC. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci 2012; 33:35-41; PMID:22032984; http://dx.doi.org/10.1016/j.tips.2011.09.004
113. Ma A, Koka R, Burkett P. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol 2006; 24:657-79; PMID:16551262; http://dx.doi.org/10.1146/annurev.immunol.24.021605.090727
114. Fry TJ, Mackall CL. The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J Immunol 2005; 174:6571-6; PMID:15905493
115. Rosenberg SA, Sportès C, Ahmadzadeh M, Fry TJ, Ngo LT, Schwarz SL, Stetler-Stevenson M, Morton KE, Mavroukakis SA, Morre M, et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother 2006; 29:313-9; PMID:16699374; http://dx.doi.org/10.1097/01.cji.0000210386.55951.c2
116. Sportès C, Babb RR, Krumlauf MC, Hakim FT, Steinberg SM, Chow CK, Brown MR, Fleisher TA, Noel P, Maric I, et al. Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin Cancer Res 2010; 16:727-35; PMID:20068111; http://dx.doi.org/10.1158/1078-0432.CCR-09-1303
117. Lundström W, Fewkes NM, Mackall CL. IL-7 in human health and disease. Semin Immunol 2012; 24:218-24; PMID:22410365; http://dx.doi.org/10.1016/j.smim.2012.02.005
118. Lévy Y, Sereti I, Tambussi G, Routy JP, Lelièvre JD, Delfraissy JF, Molina JM, Fischl M, Goujard C, Rodriguez B, et al. Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clin Infect Dis 2012; 55:291-300; PMID:22550117; http://dx.doi.org/10.1093/cid/cis383
119. Unsinger J, Burnham CA, McDonough J, Morre M, Prakash PS, Caldwell CC, Dunne WM Jr., Hotchkiss RS. Interleukin-7 ameliorates immune dysfunction and improves survival in a 2-hit model of fungal sepsis. J Infect Dis 2012; 206:606-16; PMID:22693226; http://dx.doi.org/10.1093/infdis/jis383
120. Unsinger J, McGlynn M, Kasten KR, Hoekzema AS, Watanabe E, Muenzer JT, McDonough JS, Tschoep J, Ferguson TA, McDunn JE, et al. IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. J Immunol 2010; 184:3768-79; PMID:20200277; http://dx.doi.org/10.4049/jimmunol.0903151
121. Venet F, Foray AP, Villars-Méchin A, Malcus C, Poitevin-Later F, Lepape A, Monneret G. IL-7 restores lymphocyte functions in septic patients. J Immunol 2012; 189:5073-81; PMID:23053510; http://dx.doi.org/10.4049/jimmunol.1202062
122. Sportès C, Hakim FT, Memon SA, Zhang H, Chua KS, Brown MR, Fleisher TA, Krumlauf MC, Babb RR, Chow CK, et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med 2008; 205:1701-14; PMID:18573906; http://dx.doi.org/10.1084/jem.20071681
123. Morre M, Beq S. Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival. Target Oncol 2012; 7:55-68 PMID:22383042; http://dx.doi.org/10.1007/s11523-012-0210-4
124. Sereti I, Dunham RM, Spritzler J, Aga E, Proschan MA, Medvik K, Battaglia CA, Landay AL, Pahwa S, Fischl MA, et al.; ACTG 5214 Study Team. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 2009; 113:6304-14; PMID:19380868; http://dx.doi.org/10.1182/ blood-2008-10-186601
125. Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunol Rev 2008; 222:357-68; PMID:18364014; http://dx.doi.org/10.1111/j.1600-065X.2008.00604.x
126. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26:677-704; PMID:18173375; http://dx.doi.org/10.1146/annurev.immunol.26.021607.090331
127. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 2007; 8:239-45; PMID:17304234; http://dx.doi.org/10.1038/ni1443
128. Lázár-Molnár E, Gácser A, Freeman GJ, Almo SC, Nathenson SG, Nosanchuk JD. The PD-1/PD-L costimulatory pathway critically affects host resistance to the pathogenic fungus Histoplasma capsulatum. Proc Natl Acad Sci U S A 2008; 105:2658-63; PMID:18268348; http://dx.doi.org/10.1073/pnas.0711918105
129. Brahmamdam P, Inoue S, Unsinger J, Chang KC, McDunn JE, Hotchkiss RS. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol 2010; 88:233-40; PMID:20483923; http://dx.doi.org/10.1189/jlb.0110037
130. Zhang Y, Zhou Y, Lou J, Li J, Bo L, Zhu K, Wan X, Deng X, Cai Z. PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction. Crit Care 2010; 14:R220; PMID:21118528; http://dx.doi.org/10.1186/cc9354
131. Huang X, Venet F, Wang YL, Lepape A, Yuan Z, Chen Y, Swan R, Kherouf H, Monneret G, Chung CS, et al. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc Natl Acad Sci U S A 2009; 106:6303-8; PMID:19332785; http://dx.doi.org/10.1073/pnas.0809422106
132. Guignant C, Lepape A, Huang X, Kherouf H, Denis L, Poitevin F, Malcus C, Chéron A, Allaouchiche B, Gueyffier F, et al. Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Crit Care 2011; 15:R99; PMID:21418617; http://dx.doi.org/10.1186/cc10112
133. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
134. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694
135. Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, Hurchla MA, Zimmerman N, Sim J, Zang X, et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 2003; 4:670-9; PMID:12796776; http://dx.doi.org/10.1038/ni944
136. Compaan DM, Gonzalez LC, Tom I, Loyet KM, Eaton D, Hymowitz SG. Attenuating lymphocyte activity: the crystal structure of the BTLAHVEM complex. J Biol Chem 2005; 280:39553-61; PMID:16169851; http://dx.doi.org/10.1074/jbc.M507629200
137. Shubin NJ, Chung CS, Heffernan DS, Irwin LR, Monaghan SF, Ayala A. BTLA expression contributes to septic morbidity and mortality by inducing innate inflammatory cell dysfunction. J Leukoc Biol 2012; 92:593-603; PMID:22459947; http://dx.doi.org/10.1189/jlb.1211641
138. Jin HT, Jeong YH, Park HJ, Ha SJ. Mechanism of T cell exhaustion in a chronic environment. BMB Rep 2011; 44:217-31; PMID:21524346; http://dx.doi.org/10.5483/BMBRep.2011.44.4.217
139. Ngiow SF, Teng MW, Smyth MJ. Prospects for TIM3-Targeted Antitumor Immunotherapy. Cancer Res 2011; 71:6567-71; PMID:22009533; http://dx.doi.org/10.1158/0008-5472.CAN-11-1487
140. Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng MW, Smyth MJ. Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res 2011; 71:3540-51; PMID:21430066; http://dx.doi.org/10.1158/0008-5472.CAN-11-0096
141. Sierro S, Romero P, Speiser DE. The CD4-like molecule LAG-3, biology and therapeutic applications. Expert Opin Ther Targets 2011; 15:91-101; PMID:21142803; http://dx.doi.org/10.1517/14712598.2011.540563
142. Savoldo B, Huls MH, Liu Z, Okamura T, Volk HD, Reinke P, Sabat R, Babel N, Jones JF, Webster-Cyriaque J, et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood 2002; 100:4059-66; PMID:12393655; http://dx.doi.org/10.1182/blood-2002-01-0039
143. Wagner TH, Drewry AM, Macmillan S, Dunne WM, Chang KC, Karl IE, Hotchkiss RS, Cobb JP. Surviving sepsis: bcl-2 overexpression modulates splenocyte transcriptional responses in vivo. Am J Physiol Regul Integr Comp Physiol 2007; 292:R1751-9; PMID:17234957; http://dx.doi.org/10.1152/ajpregu.00656.2006
144. Coopersmith CM, Chang KC, Swanson PE, Tinsley KW, Stromberg PE, Buchman TG, Karl IE, Hotchkiss RS. Overexpression of Bcl-2 in the intestinal epithelium improves survival in septic mice. Crit Care Med 2002; 30:195-201; PMID:11902262; http://dx.doi.org/10.1097/00003246-200201000-00028
145. Hotchkiss RS, Tinsley KW, Swanson PE, Chang KC, Cobb JP, Buchman TG, Korsmeyer SJ, Karl IE. Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc Natl Acad Sci U S A 1999; 96:14541-6; PMID:10588741; http://dx.doi.org/10.1073/pnas.96.25.14541
146. Bommhardt U, Chang KC, Swanson PE, Wagner TH, Tinsley KW, Karl IE, Hotchkiss RS. Akt decreases lymphocyte apoptosis and improves survival in sepsis. J Immunol 2004; 172:7583-91; PMID:15187138
147. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007; 117:1466-76; PMID:17549249; http://dx.doi.org/10.1172/JCI32446
148. June CH. Principles of adoptive T cell cancer therapy. J Clin Invest 2007; 117:1204-12; PMID:17476350; http://dx.doi.org/10.1172/JCI31446
149. Dyson A, Singer M. Animal models of sepsis: why does preclinical efficacy fail to translate to the clinical setting? Crit Care Med 2009; 37(Suppl):S30-7; PMID:19104223; http://dx.doi.org/10.1097/CCM.0b013e3181922bd3
150. Esmon CT. Why do animal models (sometimes) fail to mimic human sepsis? Crit Care Med 2004; 32(Suppl):S219-22; PMID:15118521; http://dx.doi.org/10.1097/01.CCM.0000127036.27343.48
151. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L, et al.; Inflammation and Host Response to Injury, Large Scale Collaborative Research Program. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A 2013; 110:3507-12; PMID:23401516; http://dx.doi.org/10.1073/pnas.1222878110
152. Standiford TJ, Strieter RM, Lukacs NW, Kunkel SL. Neutralization of IL-10 increases lethality in endotoxemia. Cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor. J Immunol 1995; 155:2222-9; PMID:7636269